Publisher: American College of Physicians   (Total: 4 journals)   [Sort by number of followers]

Showing 1 - 4 of 4 Journals sorted alphabetically
ACP Hospitalist     Full-text available via subscription   (Followers: 9)
ACP Internist     Full-text available via subscription   (Followers: 10)
ACP J. Club     Full-text available via subscription   (Followers: 11)
Annals of Internal Medicine     Full-text available via subscription   (Followers: 386, SJR: 7.466, CiteScore: 4)
Similar Journals
Journal Cover
Annals of Internal Medicine
Journal Prestige (SJR): 7.466
Citation Impact (citeScore): 4
Number of Followers: 386  
 
  Full-text available via subscription Subscription journal
ISSN (Print) 0003-4819 - ISSN (Online) 1539-3704
Published by American College of Physicians Homepage  [4 journals]
  • Annals for Educators - 5 May 2020
    • Authors: Taichman DB.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals On Call - Striving to Decrease Hospital Infection
    • Authors: Centor RM; Meddings J.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Graphic Medicine - Dr. Mom: Little Pharma
    • Authors: Farris GE.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Graphic Medicine - White Coat
    • Authors: Taing L.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Eosinophilic Esophagitis
    • Authors: Katzka DA.
      Abstract: Eosinophilic esophagitis (EoE) is a relatively new disease that has reached an incidence similar to that of Crohn disease and ulcerative colitis. With this increased presence, greater recognition is essential. This applies both to children with nonspecific but potentially debilitating symptoms and to adults who have spent years behaviorally compensating for narrow esophageal strictures. The pathogenesis of EoE is rapidly being unraveled and is based on initiation of a type II allergic response to specific food antigens, leading to dense esophageal eosinophilia, chronic inflammation, and esophageal fibrosis. With greater familiarity and understanding of EoE, treatments are evolving, including identification and avoidance of food antigens; broad applications of topical steroids; and, eventually, pathway-specific biologic therapy.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Correction: In the Clinic: Acute Colonic Diverticulitis
    • PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Correction: Recommended Adult Immunization Schedule, United States, 2020
    • PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Johnston BC; Zeraatkar D, Vernooij RM, et al.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Gong CL; Zawadzki NK, Zawadzki R, et al.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Wan Y; Wang F.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Rosenfeld RM.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Westman EC.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unprocessed Red Meat and Processed Meat Consumption
    • Authors: Meyer DA.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Graphic Medicine - One of My Demons: Crying (or a Lack of)
    • Authors: Bellchambers AS.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Clinical Decision Making: Translating Population Evidence to
           Individual Patients
    • Authors: Armstrong KA; Metlay JP.
      Abstract: This paper in the Annals Clinical Decision Making series explains a practical approach to evaluating whether the conclusions of studies involving many patients or whole populations may be confidently applied to the care of an individual patient.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Clinical Decision Making: Nurturing Our Core Skills
    • Authors: Taichman DB; Williams SV, Laine C.
      Abstract: Making diagnostic and management decisions is the core skill of physicians. The editors introduce the Annals Clinical Decision Making series, a collection of coordinated articles designed to help all physicians hone their skills.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Clinical Decision Making: Weighing Evidence to Inform Clinical
           Decisions
    • Authors: Metlay JP; Armstrong KA.
      Abstract: Deciding when recently published evidence should alter practice can be daunting. This article in the Annals Clinical Decision Making series discusses the care of a patient with a common problem and recently published studies to illustrate an approach to weighing new evidence not yet considered by practice guidelines that conflicts with existing recommendations.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Clinical Decision Making: Using a Diagnostic Test
    • Authors: Armstrong KA; Metlay JP.
      Abstract: Diagnostic testing is an essential tool in clinical decision making. This article in the Annals Clinical Decision Making series reviews core principles underlying the approach to choosing and interpreting diagnostic tests for individual patients.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals On Call - COVID-19: Is Chloroquine the Answer'
    • Authors: Centor RM; Kim A, Sparks JA.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Annals Graphic Medicine - True Tales From the Outbreak: Life in the Hot
           Zone
    • Authors: Thomas A.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Isradipine Versus Placebo in Early Parkinson Disease
    • PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Love in the Time of Corona
    • Authors: Benatti SV.
      Abstract: One of the most painful aspects of this pandemic is the irremediable separation of patients from their families at the end of their lives.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • A Clinical Trial of Isradipine: What Went Wrong'
    • Authors: Maiti B; Perlmutter JS.
      Abstract: The Parkinson Study Group STEADY-PD III Investigators reported the results of a randomized controlled trial evaluating the effect of isradipine, a dihydropyridine calcium-channel blocker, on clinical progression of Parkinson disease. The editorialists discuss the findings and the need for more reliable in vivo biomarkers of Parkinson disease progression and measures of specific target engagement.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Isradipine Versus Placebo in Early Parkinson Disease A Randomized Trial
    • Authors: .
      Abstract: Background:Studies suggest that dihydropyridine calcium-channel blockers may be associated with reduced risk for Parkinson disease (PD).Objective:To assess the effect of isradipine, a dihydropyridine calcium-channel blocker, on the rate of clinical progression of PD.Design:Multicenter, randomized, parallel-group, double-blind, placebo-controlled trial. (ClinicalTrials.gov: NCT02168842)Setting:57 Parkinson Study Group sites in North America.Participants:Patients with early-stage PD (duration <3 years) who were not taking dopaminergic medications at enrollment.Intervention:5 mg of immediate-release isradipine twice daily or placebo for 36 months.Measurements:The primary outcome was change in the Unified Parkinson's Disease Rating Scale (UPDRS) parts I to III score measured in the antiparkinson medication “ON” state between baseline and 36 months. Secondary outcomes included time to initiation and use of antiparkinson medications, time to onset of motor complications, change in nonmotor disability, and quality-of-life measures.Results:336 patients were randomly assigned (mean age, 62 years [SD, 9]; 68% men; disease duration, 0.9 year [SD, 0.7]; mean UPDRS part I to III score, 23.1 [SD, 8.6]); 95% of patients completed the study. Adjusted least-squares mean changes in total UPDRS score in the antiparkinson medication ON state over 36 months for isradipine and placebo recipients were 2.99 (95% CI, 0.95 to 5.03) points versus 3.26 (CI, 1.25 to 5.26) points, respectively, with a treatment effect of −0.27 (CI, −3.02 to 2.48) point (P = 0.85). Statistical adjustment for antiparkinson medication use did not change the findings. Secondary outcomes showed no effect of isradipine treatment. The most common adverse effects of isradipine were edema and dizziness.Limitation:The isradipine dose may have been insufficient to engage the target calcium channels associated with neuroprotective effects.Conclusion:Long-term treatment with immediate-release isradipine did not slow the clinical progression of early-stage PD.Primary Funding Source:National Institute of Neurological Disorders and Stroke.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Improving How State Medical Boards Ask Physicians About Mental Health
           Diagnoses: A Case Study From New Mexico
    • Authors: Barrett E; Lawrence E, Waldman D, et al.
      Abstract: State-based medical license applications often ask about mental health diagnoses and treatment in terms that stigmatize mental illness, which inadvertently discourages physicians from seeking care. In this article, the authors describe a recent collaboration that resulted in updated and destigmatized language on their state's medical license application.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a
           Patient With COVID-19
    • Authors: Zhang H; Zhou P, Wei Y, et al.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • How Should U.S. Hospitals Prepare for Coronavirus Disease 2019
           (COVID-19)'
    • Authors: Chopra V; Toner E, Waldhorn R, et al.
      Abstract: Estimates suggest that COVID-19 will stress bed capacity, equipment, and health care personnel in U.S. hospitals in ways not previously experienced. How can health systems prepare to care for a large influx of patients with this disease'
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Coronavirus Disease 2019 (COVID-19): Protecting Hospitals From the
           Invisible
    • Authors: Klompas M.
      Abstract: COVID-19 is optimized to spread widely: Its signs and symptoms are largely indistinguishable from those of other respiratory viruses. This commentary specifically addresses best ways to protect our hospitals against COVID-19.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • How Much Are We Willing to Pay for Preexposure Prophylaxis in the United
           States'
    • Authors: del Rio C; Armstrong WS.
      Abstract: Walensky and colleagues' cost-effectiveness analysis estimated the potential clinical benefits of tenofovir alafenamide–emtricitabine (F/TAF) and the resultant cost savings of lower risk for renal failure and fractures versus the increased cost of branded F/TAF compared with generic tenofovir disoproxil fumarate–emtricitabine for HIV preexposure prophylaxis (PrEP). The editorialists believe that the findings make it clear that shifting to F/TAF as first-line PrEP for all should not be universally recommended if the goal is to end AIDS in the United States.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly
           Reported Confirmed Cases: Estimation and Application
    • Authors: Lauer SA; Grantz KH, Bi Q, et al.
      Abstract: Background:A novel human coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was identified in China in December 2019. There is limited support for many of its key epidemiologic features, including the incubation period for clinical disease (coronavirus disease 2019 [COVID-19]), which has important implications for surveillance and control activities.Objective:To estimate the length of the incubation period of COVID-19 and describe its public health implications.Design:Pooled analysis of confirmed COVID-19 cases reported between 4 January 2020 and 24 February 2020.Setting:News reports and press releases from 50 provinces, regions, and countries outside Wuhan, Hubei province, China.Participants:Persons with confirmed SARS-CoV-2 infection outside Hubei province, China.Measurements:Patient demographic characteristics and dates and times of possible exposure, symptom onset, fever onset, and hospitalization.Results:There were 181 confirmed cases with identifiable exposure and symptom onset windows to estimate the incubation period of COVID-19. The median incubation period was estimated to be 5.1 days (95% CI, 4.5 to 5.8 days), and 97.5% of those who develop symptoms will do so within 11.5 days (CI, 8.2 to 15.6 days) of infection. These estimates imply that, under conservative assumptions, 101 out of every 10 000 cases (99th percentile, 482) will develop symptoms after 14 days of active monitoring or quarantine.Limitation:Publicly reported cases may overrepresent severe cases, the incubation period for which may differ from that of mild cases.Conclusion:This work provides additional evidence for a median incubation period for COVID-19 of approximately 5 days, similar to SARS. Our results support current proposals for the length of quarantine or active monitoring of persons potentially exposed to SARS-CoV-2, although longer monitoring periods might be justified in extreme cases.Primary Funding Source:U.S. Centers for Disease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of General Medical Sciences, and Alexander von Humboldt Foundation.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Comparative Pricing of Branded Tenofovir Alafenamide–Emtricitabine
           Relative to Generic Tenofovir Disoproxil Fumarate–Emtricitabine for HIV
           Preexposure Prophylaxis A Cost-Effectiveness Analysis
    • Authors: Walensky RP; Horn T, McCann NC, et al.
      Abstract: Background:Tenofovir alafenamide–emtricitabine (F/TAF) was recently approved as a noninferior and potentially safer option than tenofovir disoproxil fumarate–emtricitabine (F/TDF) for HIV preexposure prophylaxis (PrEP) in the United States.Objective:To estimate the greatest possible clinical benefits and economic savings attributable to the improved safety profile of F/TAF and the maximum price payers should be willing to pay for F/TAF over generic F/TDF.Design:Cost-effectiveness analysis.Data Sources:Published literature on F/TDF safety (in persons with and those without HIV) and the cost and quality-of-life effects of fractures and end-stage renal disease (ESRD).Target Population:Age-stratified U.S. men who have sex with men (MSM) using PrEP.Time Horizon:Five years.Perspective:Health care sector.Intervention:Preexposure prophylaxis with F/TAF versus F/TDF.Outcome Measures:Fractures averted, cases of ESRD averted, quality-adjusted life-years (QALYs) saved, costs, incremental cost-effectiveness ratios (ICERs), and maximum justifiable price for F/TAF compared with generic F/TDF.Results of Base-Case Analysis:Over a 5-year horizon, compared with F/TDF, F/TAF averted 2101 fractures and 25 cases of ESRD for the 123 610 MSM receiving PrEP, with an ICER of more than $7 million per QALY. At a 50% discount for generic F/TDF ($8300 per year) and a societal willingness to pay up to $100 000 per QALY, the maximum fair price for F/TAF was $8670 per year.Results of Sensitivity Analysis:Among persons older than 55 years, the ICER for F/TAF remained more than $3 million per QALY and the maximum permissible fair price for F/TAF was $8970 per year. Results were robust to alternative time horizons and PrEP-using population sizes.Limitation:Intermittent use and on-demand PrEP were not considered.Conclusion:In the presence of a generic F/TDF alternative, the improved safety of F/TAF is worth no more than an additional $370 per person per year.Primary Funding Source:National Institute of Allergy and Infectious Diseases, National Institute on Drug Abuse, National Institute of Mental Health, and Massachusetts General Hospital Executive Committee on Research.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unilateral Facial Paralysis During an Airline Flight
    • Authors: Hunter AJ.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
  • Unwanted Medication Disposal: Audit of California Pharmacy Advice
    • Authors: Selekman RE; Gaither TW, Kornberg Z, et al.
      PubDate: Tue, 05 May 2020 00:00:00 GMT
       
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
 


Your IP address: 18.204.42.98
 
Home (Search)
API
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-